Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metachromatic leukodystrophy: recent research developments.

Volkmar Gieselmann1

  • 1Institute of Physiological Chemistry, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. gieselmann@institut.physiochem.uni-bonn.de

Journal of Child Neurology
|October 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta arrestin 1 is a key regulator of pulmonary vascular tone.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

ARSA Variants Associated With Cognitive Decline and Long-Term Preservation of Motor Function in Metachromatic Leukodystrophy.

Journal of inherited metabolic disease·2025
Same author

Publisher Correction: Starvation-induced metabolic rewiring affects mTORC1 composition in vivo.

Scientific reports·2025
Same author

Starvation-induced metabolic rewiring affects mTORC1 composition in vivo.

Scientific reports·2024
Same author

Engineered arylsulfatase A with increased activity, stability and brain delivery for therapy of metachromatic leukodystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2023
Same author

Proteomic investigation of neural stem cell to oligodendrocyte precursor cell differentiation reveals phosphorylation-dependent Dclk1 processing.

Cellular and molecular life sciences : CMLS·2023

Bone marrow stem cell gene therapy showed limited success for metachromatic leukodystrophy, a rare genetic disorder. While enzyme activity increased, sulfatide storage and brain demyelination were not effectively treated.

Area of Science:

  • Biochemistry
  • Genetics
  • Neuroscience

Background:

  • Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder caused by arylsulfatase A deficiency, leading to sulfatide accumulation and progressive demyelination.
  • The disease results in severe, ultimately fatal, neurological symptoms, with genetic heterogeneity observed in patients.

Purpose of the Study:

  • To investigate the therapeutic potential of bone marrow stem cell-based gene therapy for MLD.
  • To explore the underlying pathogenesis of demyelination in MLD, focusing on myelin protein alterations.

Main Methods:

  • Utilized an arylsulfatase A-deficient knockout mouse model exhibiting some MLD features.
  • Administered bone marrow stem cell-based gene therapy to assess enzyme activity and sulfatide storage.

Related Experiment Videos

  • Analyzed myelin protein content and distribution in deficient mice.

    • Main Results:

    • Treated mice showed increased arylsulfatase A activity in various tissues, including the brain, but disappointing effects on sulfatide storage.
    • Positive effects on lipid storage were observed only in the kidney and liver of animals with very high enzyme levels; no effect was seen in the brain.
    • Reduced myelin and lymphocyte protein (MAL) and altered proteolipid distribution were observed in the myelin of deficient mice.

    Conclusions:

    • Bone marrow stem cell-based gene therapy may have limited value in treating MLD due to lack of efficacy in the brain.
    • Further research is needed to understand how sulfatide storage impacts oligodendrocyte metabolism and contributes to demyelination.